Worldwide Tissue Microarray Market is Projected to Grow at a CAGR of 10.88% by 2023

Market Research Future has a cooked research report on the global tissue microarray market.

Tissue microarrays are paraffin blocks that are created by separating cylindrical tissue cores from different paraffin donor blocks and re-embedding these into a microarray at defined array coordinates. With the help of tissue microarray up to 1000 tissue samples can be arrayed into a single paraffin piece. It allows simultaneous analysis of molecules present in DNA, mRNA, and protein under identical and standardized conditions on a single glass slide. This adaptable strategy in which data analysis is automated, facilitates retrospective and prospective human tissue studies.

Increasing application of tissue microarray in drug discovery and oncology, automated analysis of results, and influence of technology are some of the major factors that fosters the growth of the global tissue microarray market. Moreover, wide applications of tissue microarray in pathology is another factor, which is impelling the growth of tissue microarray market.

The global tissue microarray market is expected to grow at a CAGR of 10.88% during the forecast period 2017-2023.

Taste the market data and market information presented through more than 188 market data tables and figures spread over 182 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “tissue microarray market research report–Global forecast till 2023.”

Get a sample report at https://www.marketresearchfuture.com/sample_request/1213 .

Major Players in the tissue microarray Market

Some of the key players in the global market are Agilent Technologies, Illumina, Inc., Protein Biotechnologies Inc., Asterand Bioscience, Pantomics Inc., Applied Microarrays, Arrayit, Phalanx Biotech, Qiagen, Takara Bio, Perkin Elmer, Merck Sharp & Dohme Corp, and general electric and others.

The global tissue microarray market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas is the leading market across the globe on account of constantly increasing cancer patient population, increasing number of cases in children, and increasing government support for research in healthcare domain and it is likely to flourish the Americas market over the review period.

Europe holds the second position in the market due to development in healthcare domain. During the last 30 years, in Europe biotechnology industry has developed gradually. Even though in Germany federal support programs started very early to target biotechnology, the innovative performance of this sector has been lagging behind that of the US, where the federal support was less direct earlier. Advances in technology in the healthcare sector have minimized human effort and increased the quality of patient care services, which will boost the market growth.

Asia Pacific is expected to be the fastest growing market owing to the concentration of emerging player and focus of established market leaders in this region. Moreover, the rising incidence of cancer in Asia Pacific has prompted suppliers and manufacturers to expand their market reach and to enter emerging markets. According to the Centers for Disease Control and Prevention (CDC), life-threatening or chronic diseases such as stroke, heart disease, cancer, diabetes, and chronic respiratory diseases, kidney diseases were the leading cause of death in 2014.

On the other hand, the Middle East & Africa owns the minimum market share of the tissue microarray market due to less development in healthcare services such as new and advanced diagnosis & treatment methods in healthcare domain.

Segmentation

The global tissue microarray market is segmented on the basis of procedure, technology, application, and end user.

On the basis procedure, it is segmented into immunohistochemistry, fluorescent in-situ hybridization, and frozen tissue array.

On the basis of technology, it is segmented into DNA microarray, polymerase chain reaction, next-generation sequencing, northern blotting, and western blotting.

On the basis of application, it is segmented in to oncology, gene expression profiling, SNP detection, double-stranded B-DNA microarrays, and comparative genomic hybridization, and sequencing bioinformatics.

On the basis of end user, it is segmented into pharmaceutical and biotechnological companies, research organization, and others.

Browse Complete Report at  https://www.marketresearchfuture.com/reports/tissue-microarray-market-1213 .

The market for tissue microarray treatment is growing extensively. It is a practical and efficient tool for high-throughput molecular analysis of tissues that help to identify new diagnostic and prognostic markers. It also targets human cancers and has a range of potential applications in basic research, prognostic oncology, and drug discovery. The growing need for targeted treatments for various chronic diseases such as cancer, genetic diseases, and others has boosted the growth of the market

Increasing application in drug discovery is one of the major factors driving the market growth. During drug research and development, the risk of product failure is high. Moreover, advancement in molecular methods have massively simplified the discovery of potential molecular targets for gene-specific therapy. Application in drug discovery has generated a massive demand for such supposed targets and to meet such demand human tissue analysis is needed. Nevertheless, the need for analysis of large numbers of well-characterized human tissues constitutes a major role in the drug discovery and development. Earlier, tissue analysis used to be done in slide-by-slide manner, which was time consuming, expensive, and difficult to operate.

Increasing prevalence of cancer is one of the important factors that drives the growth of the tissue microarray market. According to the American Cancer Society, in 2017, about 1 in 8 the U.S. women (about 12%) predicted to develop invasive breast cancer over the course of her lifetime. In 2017, an estimated 252,710 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 63,410 new cases of non-invasive (in situ) breast cancer.

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us
Market Research Future
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com

This release was published on openPR.